AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
B4GALNT3 | Beta-1,4-N-acetyl-galactosaminyl transferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
BCAS1 | Breast carcinoma amplified sequence 1 | | | | | | Tissue enhanced |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CAPN9 | Calpain 9 | Enzymes
| | | | | Tissue enhanced |
FOXA2 | Forkhead box A2 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
FOXQ1 | Forkhead box Q1 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
GALNT5 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5) | Enzymes
| | | | | Tissue enhanced |
GALNT6 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
IL17REL | Interleukin 17 receptor E-like | | | | | | Tissue enhanced |
LGALS9B | Lectin, galactoside-binding, soluble, 9B | | | | | | Tissue enhanced |
LGALS9C | Lectin, galactoside-binding, soluble, 9C | | | | | | Tissue enhanced |
MLPH | Melanophilin | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
MUC1 | Mucin 1, cell surface associated | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
NQO1 | NAD(P)H dehydrogenase, quinone 1 | Cancer-related genes Enzymes
| | | | | Tissue enhanced |
RAB27B | RAB27B, member RAS oncogene family | Plasma proteins
| | | | | Tissue enhanced |
RASEF | RAS and EF-hand domain containing | | | | | | Tissue enhanced |
RFX6 | Regulatory factor X, 6 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
SCGN | Secretagogin, EF-hand calcium binding protein | Plasma proteins
| | | | | Tissue enhanced |
SMIM6 | Small integral membrane protein 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
SSTR1 | Somatostatin receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
SULT1C2 | Sulfotransferase family, cytosolic, 1C, member 2 | Plasma proteins
| | | | | Tissue enhanced |
TMC5 | Transmembrane channel-like 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
TPSD1 | Tryptase delta 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
UPK1B | Uroplakin 1B | Predicted membrane proteins
| | | | | Tissue enhanced |
VILL | Villin-like | Plasma proteins
| | | | | Tissue enhanced |